CAC
SAGE

Cowen and Company’s Sage Therapeutics SAGE Stock Holding History

Cowen and Company’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-161,186
Closed -$1.16M – 254
2024
Q3 		$1.16M Sell
161,186
-53,046
-25% -$486K 0.04% 146
2024
Q2 		$2.33M Sell
214,232
-218,846
-51% -$2.8M 0.06% 110
2024
Q1 		$8.12M Sell
433,078
-906,893
-68% -$20.9M 0.31% 30
2023
Q4 		$29M Buy
+1,339,971
New +$26.6M 1.9% 13

Other funds holding SAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Cowen and Company's SAGE Position: Q4 2024 in Review

Cowen and Company sold out of Sage Therapeutics (SAGE) in Q4 2024, closing a stake of 161,186 shares — an estimated $1.16M sold.

Cowen and Company first reported a position in SAGE in Q4 2023 and held it in 4 quarters. The position peaked at $29M in Q4 2023. 177 funds tracked by Wall St. Rank hold SAGE as of Q4 2024.

  • Cowen and Company reported no remaining Sage Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Cowen and Company sold 161,186 Sage Therapeutics shares in Q4 2024, an estimated $1.16M.
  • Cowen and Company first reported a position in Sage Therapeutics in Q4 2023 and held it in 4 quarters.
  • Cowen and Company's Sage Therapeutics position peaked at $29M in Q4 2023.
  • 177 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2024.

Based on Cowen and Company's 13F filing for Q4 2024.